

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS
03 AUG 12 PM 1:45

00000273039

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Ricchetti Incorporated</u>		
2. Address <input type="checkbox"/> Check if different than previously reported <u>1001 G Street NW Suite 700 East</u>		
3. Principal Place of Business (if different from line 2) City: <u>Washington</u> State/Zip (or Country) <u>DC 20001</u>		
4. Contact Name <u>James Heimbsch</u>	Telephone <u>(202) 879-9367</u>	E-mail (optional)
7. Client Name <input type="checkbox"/> Self <u>Eli Lilly & Company</u>		5. Senate ID <u>6277</u>
		6. House ID <u>35395</u>

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobb

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>90,000⁰⁰</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$</p> <p>14. REPORTING METHOD. Check box to ind accounting method. See instructions for descriptio</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA de</p> <p><input type="checkbox"/> Method B. Reporting amounts under section Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section Internal Revenue Code</p>
--	--

Signature

Printed Name and Title James T. Heimbsch Vice President

LD-2 (REV. 6/98)

00000273040

Registrant Name Ricchetti Inc. Client Name Eli Lilly

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

Vaccine injury compensation program
S. 15 - Biodefense Improvement and Treatment for America Act

17. House(s) of Congress and Federal agencies contacted Check if None

US House
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Steve Ricchetti</u>
<u>Jeff Ricchetti</u>
<u>Lisa Kountoupes</u>
<u>James Heimbach</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature [Signature] Date 8/7/11

Printed Name and Title James T. Heimbech Vice President

Form LD-2 (Rev. 6/98)

Printed Name and Title James T. Heimbach Vice President

Form LD-2 (Rev. 6/98)

Printed Name and Title James T. Heimbech Vice President

Form LD-2 (Rev. 6/98)

Registrant Name Ricchetti Inc. Client Name Eli Lilly

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare prescription drug benefits
HR 1 - Medicare Prescription Drug and Modernization Act of 2003
S 1 Prescription Drug and Medicare Improvement Act of 2003
All aspects of above legislation as they affect pharmaceutical including coverage, costs and access provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

US Senate
US House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Steve Ricchetti
Jeff Ricchetti
Lisa Kountoupes
James Heimbrach

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature [Handwritten Signature] Date 8/7/03

Printed Name and Title James T. Heimbach Vice President

Form LD-2 (Rev. 6/98)

Printed Name and Title James T. Heimbach Vice President

Form LD-2 (Rev. 6/98)

Printed Name and Title James T. Heimbech Vice President

Form LD-2 (Rev. 6/98)

Registrant Name Ricchetti Inc. Client Name Eli Lilly

010000273046

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

N/A

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

N/A

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

TAX

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)
<u>N/A</u>		

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

N/A

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities
<u>N/A</u>			

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant or affiliated organization

N/A

8/2/10

Signature _____ Date 8/1/02

Printed Name and Title James T Heimbach Vice President

Form LD-2 (Rev. 6/98)

Page